Prevention and Treatment
of Bladder and Prostate Cancer

With more than 64,000 new cases per year in Germany, prostate cancer is the most common tumour in men over the age of 50. Early detection is crucial for recovery. Thanks to constantly improved diagnosis and therapy, survival rates have risen significantly.

The S3 guideline on prostate cancer recommends testing PSA levels from the age of 45. The prostate-specific antigen (PSA) is formed by certain cells of the prostate, also called the prostate gland. If cancer cells have formed in the prostate, the PSA level is often elevated. In this case, magnetic resonance imaging (MRI) can be performed.

Diagnosis by palpation (palpation examination) is no longer officially recommended since 2025.

The CORAZOR^® Biopsy Device , the Puncture Biopsy Cannuals and the Fine Biopsy Needles from UROMED enable targeted sampling and precise diagnostics, thereby facilitating treatment decisions.

Urinary Bladder Cancer is the fourth most common tumour in men. In women, it ranks 13th. With around 23,200 new cases in men and 7,500 in women per year, this tumour is one of the most common carcinomas in Germany. Included in these figures are both invasive and non-invasive carcinomas, as well as in situ tumours and unclear changes. A typical symptom of a bladder tumour is painless macrohaematuria, defined as the presence of blood in the urine.

Treatment for bladder cancer depends on how far the cancer has penetrated and the degree of differentiation of the tumour. Treatment usually begins with transurethral resection (TUR) of the tumour. Starting this treatment early can significantly improve recovery chances. In some cases, this treatment removes the tumour completely. This procedure is also used to determine the degree of malignancy and the depth of invasion.

We then recommend not only the instillation of chemotherapy agents, but also the use of electromotive drug administration (EMDA^®*), so that drugs such as Mitomycin can penetrate deep into the tissue where it can take effect.

Studies show better results compared to the previous standard therapy (BCG) in terms of symptom-free time with regard to relapse or progression.